fda tirzepatide osa approves weight loss drug found in Mounjaro for use in sleep apnea patients FDA Approved Zepbound: Key Info

Lifestyle change remains the foundation, but new treatments like tirzepatide offer powerful new tools to help people lower their risk

The drugs disrupt appetite signals by making people feel fuller sooner and leave food in the stomach for longer

Whether adding GIP agonism to the GLP-1/glucagon backbone yields a better efficacy-tolerability balance than survodutides two-receptor design is an open comparative question

But even before the drugs officially hit the market for weight loss, doctors had noticed the benefits and began prescribing off-label for patients who needed to shed pounds

Rising patient awareness and improving affordability also contribute to expanding GLP-1 drug uptake

A related anorectal condition